We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unveiling Teleflex (TFX) Q4 Outlook: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Teleflex (TFX - Free Report) will report quarterly earnings of $3.73 per share in its upcoming release, pointing to a year-over-year decline of 4.1%. It is anticipated that revenues will amount to $925.96 million, exhibiting an increase of 16.4% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone a downward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Teleflex metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus estimate for 'Net Revenues- Interventional' stands at $274.02 million. The estimate suggests a change of +70.8% year over year.
Analysts expect 'Net Revenues- Interventional Urology' to come in at $80.73 million. The estimate points to a change of -4.9% from the year-ago quarter.
The average prediction of analysts places 'Net Revenues- OEM' at $85.31 million. The estimate indicates a change of -0.1% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net Revenues- Vascular Access' will likely reach $205.12 million. The estimate points to a change of +8.4% from the year-ago quarter.
Analysts predict that the 'Net Revenues- Anesthesia' will reach $99.90 million. The estimate suggests a change of +4.8% year over year.
According to the collective judgment of analysts, 'Net Revenues- Other' should come in at $64.41 million. The estimate indicates a change of +10.7% from the prior-year quarter.
Based on the collective assessment of analysts, 'Net Revenues- Surgical' should arrive at $128.49 million. The estimate points to a change of +5.4% from the year-ago quarter.
Analysts' assessment points toward 'Geographic Revenues- Americas' reaching $577.44 million. The estimate indicates a change of +6.8% from the prior-year quarter.
The consensus among analysts is that 'Geographic Revenues- EMEA' will reach $203.23 million. The estimate points to a change of +26.2% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Geographic Revenues- Asia' of $115.99 million. The estimate indicates a change of +23.9% from the prior-year quarter.
Shares of Teleflex have demonstrated returns of +7.3% over the past month compared to the Zacks S&P 500 composite's -0.3% change. With a Zacks Rank #4 (Sell), TFX is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Unveiling Teleflex (TFX) Q4 Outlook: Wall Street Estimates for Key Metrics
Wall Street analysts forecast that Teleflex (TFX - Free Report) will report quarterly earnings of $3.73 per share in its upcoming release, pointing to a year-over-year decline of 4.1%. It is anticipated that revenues will amount to $925.96 million, exhibiting an increase of 16.4% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone a downward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Teleflex metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus estimate for 'Net Revenues- Interventional' stands at $274.02 million. The estimate suggests a change of +70.8% year over year.
Analysts expect 'Net Revenues- Interventional Urology' to come in at $80.73 million. The estimate points to a change of -4.9% from the year-ago quarter.
The average prediction of analysts places 'Net Revenues- OEM' at $85.31 million. The estimate indicates a change of -0.1% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net Revenues- Vascular Access' will likely reach $205.12 million. The estimate points to a change of +8.4% from the year-ago quarter.
Analysts predict that the 'Net Revenues- Anesthesia' will reach $99.90 million. The estimate suggests a change of +4.8% year over year.
According to the collective judgment of analysts, 'Net Revenues- Other' should come in at $64.41 million. The estimate indicates a change of +10.7% from the prior-year quarter.
Based on the collective assessment of analysts, 'Net Revenues- Surgical' should arrive at $128.49 million. The estimate points to a change of +5.4% from the year-ago quarter.
Analysts' assessment points toward 'Geographic Revenues- Americas' reaching $577.44 million. The estimate indicates a change of +6.8% from the prior-year quarter.
The consensus among analysts is that 'Geographic Revenues- EMEA' will reach $203.23 million. The estimate points to a change of +26.2% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Geographic Revenues- Asia' of $115.99 million. The estimate indicates a change of +23.9% from the prior-year quarter.
View all Key Company Metrics for Teleflex here>>>Shares of Teleflex have demonstrated returns of +7.3% over the past month compared to the Zacks S&P 500 composite's -0.3% change. With a Zacks Rank #4 (Sell), TFX is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .